Here At Last: New EU Annex On Sterile Drug Manufacturing Targets Contamination & Risk
Following two public consultations and many thousands of comments, the revised GMP Annex 1 has finally been published.
You may also be interested in...
Experts who led PDA’s interactions with EU, PIC/s and WHO authorities on first-ever comprehensive revision of sterile drug product manufacturing guidance recently shared insights on implementation priorities with the Pink Sheet.
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.